L4170
LDN-57444
≥98% (HPLC)
Synonym(s):
3-(O-acetyloxime), 5-chloro-1-[(2,5-dichlorophenyl)methyl]-1H-Indole-2,3-dione, C30, LDN 57444
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C17H11Cl3N2O3
CAS Number:
Molecular Weight:
397.64
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Quality Level
assay
≥98% (HPLC)
form
solid
storage condition
desiccated, protect from light
solubility
DMSO: 16 mg/mL
storage temp.
2-8°C
SMILES string
CC(=O)O\N=C1/C(=O)N(Cc2cc(Cl)ccc2Cl)c3ccc(Cl)cc13
InChI
1S/C17H11Cl3N2O3/c1-9(23)25-21-16-13-7-12(19)3-5-15(13)22(17(16)24)8-10-6-11(18)2-4-14(10)20/h2-7H,8H2,1H3/b21-16-
InChI key
OPQRFPHLZZPCCH-PGMHBOJBSA-N
Biochem/physiol Actions
LDN-57444 is a potent, reversible, competitive and active site-directed inhibitor of UCHL1
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Amanda J Steiman et al.
The Journal of rheumatology, 41(9), 1808-1816 (2014-08-03)
Systemic lupus erythematosus (SLE) is typically a relapsing/remitting disease. However, some patients experience prolonged remission. These patients may provide further insights into SLE pathophysiology. In this study we characterize their clinical course. Prolonged remission was defined as Systemic Lupus Erythematosus
Lorena Ruiz de Larrinaga et al.
Nutrients, 11(7) (2019-07-07)
Vegetables, once harvested and stored on supermarket shelves, continue to perform biochemical adjustments due to their modular nature and their ability to retain physiological autonomy. They can live after being harvested. In particular, the content of some essential nutraceuticals, such
Anna Wing et al.
Cancer immunology research, 6(5), 605-616 (2018-03-29)
T cells expressing chimeric antigen receptors (CART) have shown significant promise in clinical trials to treat hematologic malignancies, but their efficacy in solid tumors has been limited. Oncolytic viruses have the potential to act in synergy with immunotherapies due to